Croda acquires Solus Biotech and expands Pharma business in Asia
Croda announced that it has acquired Solus Biotech, a global leader in premium, biotechnology-derived materials, from Solus Advanced Materials.
Read moreInside Therapeutics – new member
Inside Therapeutics designs, develops and markets instruments and services for manufacturing RNA-based lipid nanoparticles.
Read moreAM-Biotech Consulting – new member
AM-Biotech Consulting offers CMC expertise.
Read moreOsivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for BroadSpectrum Influenza Vaccine Candidate, OVX836
Osiva published in The Lancet Infectious Diseases results from the company’s OVX836-003 study under the title, “Immunogenicity, safety and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: randomised, double-blind placebocontrolled, Phase 2a trial.
Read moreOsivax Announces Vaccination of First Participant in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs
Osivax Announces Vaccination of First Participant in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs.
Read more